AB0 incompatible kidney transplantation using unspecific immunoadsorption
Abstract Background A protocol for ABO-incompatible kidney transplantation with antigen specific immunoadsorption, rituximab and conventional immunosuppression has been successfully implemented in many European centers. We report an alternative method for the elimination of isoagglutinins with a num...
Gespeichert in:
| Veröffentlicht in: | Transfusion and apheresis science 2014-04, Vol.50 (2), p.263-266 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 266 |
|---|---|
| container_issue | 2 |
| container_start_page | 263 |
| container_title | Transfusion and apheresis science |
| container_volume | 50 |
| creator | Hickstein, Heiko Koball, Sebastian Lehmann, Renate Protzel, Chris Stein, Kathrin Mitzner, Steffen Hakenberg, Oliver |
| description | Abstract Background A protocol for ABO-incompatible kidney transplantation with antigen specific immunoadsorption, rituximab and conventional immunosuppression has been successfully implemented in many European centers. We report an alternative method for the elimination of isoagglutinins with a number of advantages – large amount of treatable plasma, parallel removal of other rejection-inducing antibodies, long operating life, favorable cost-benefit ratio. Method We report our first successfully treated case of an ABO-incompatible living donor kidney transplantation using Immunoadsorption with Ig-TheraSorb®. We performed 5 sessions preoperatively and one after transplantation. Per treatment session twice the calculated plasma volume (4400 ml in this patient) was treated. Results Per treatment session the IgM- isoagglutinin-titers were reduced from 1:16 to 1:1 and the IgG- isoagglutinin-titers from 1:32 to 1:2. There were no side effects and the procedure was well tolerated with good renal function 500 days post transplantation. Conclusion Ig-TheraSorb®-Immunoadsorption is an alternative method of elimination of harmful antibodies and it enables successful integration of ABO-incompatible transplantation into regular transplantation programs. |
| doi_str_mv | 10.1016/j.transci.2014.01.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1526736515</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473050214000081</els_id><sourcerecordid>1526736515</sourcerecordid><originalsourceid>FETCH-LOGICAL-c335t-6924db2ccf49d4c5d8141aca35157d716d9d473a997f5b1e166f7d48661324083</originalsourceid><addsrcrecordid>eNqFkUtv1TAQhS1ERUvhJ4CyZJPgiV_JBtRWPCpV6qJlbfnaE-TbxA52gnT_PQ73woIN3tg6OnNm_A0hb4A2QEG-3zdLMiFb37QUeEOhoVQ-IxfQqa4G2bHn5c0Vq6mg7Tl5mfOeUlDQyxfkvOUCVKfYBbm9uqaVDzZOs1n8bsTqybuAh-p3-jyasBQ9hmrNPnyv1qKh9YO3lZ-mNUTjckzz5nhFzgYzZnx9ui_Jt8-fHm--1nf3X25vru5qy5hYatm33O1aawfeO26F64CDsYYJEMopkK7Iipm-V4PYAYKUg3K8kxJYy2nHLsm7Y-6c4o8V86Inny2OZVSMa9YgWqmYLHHFKo5Wm2LOCQc9Jz-ZdNBA9UZR7_WJot4oagq6UCx1b08t1t2E7m_VH2zF8PFowPLRnx6TLhEYLDqf0C7aRf_fFh_-SbCjD96a8QkPmPdxTaFQ1KBzq6l-2Fa5bRI4LacD9guZ45rv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1526736515</pqid></control><display><type>article</type><title>AB0 incompatible kidney transplantation using unspecific immunoadsorption</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Hickstein, Heiko ; Koball, Sebastian ; Lehmann, Renate ; Protzel, Chris ; Stein, Kathrin ; Mitzner, Steffen ; Hakenberg, Oliver</creator><creatorcontrib>Hickstein, Heiko ; Koball, Sebastian ; Lehmann, Renate ; Protzel, Chris ; Stein, Kathrin ; Mitzner, Steffen ; Hakenberg, Oliver</creatorcontrib><description>Abstract Background A protocol for ABO-incompatible kidney transplantation with antigen specific immunoadsorption, rituximab and conventional immunosuppression has been successfully implemented in many European centers. We report an alternative method for the elimination of isoagglutinins with a number of advantages – large amount of treatable plasma, parallel removal of other rejection-inducing antibodies, long operating life, favorable cost-benefit ratio. Method We report our first successfully treated case of an ABO-incompatible living donor kidney transplantation using Immunoadsorption with Ig-TheraSorb®. We performed 5 sessions preoperatively and one after transplantation. Per treatment session twice the calculated plasma volume (4400 ml in this patient) was treated. Results Per treatment session the IgM- isoagglutinin-titers were reduced from 1:16 to 1:1 and the IgG- isoagglutinin-titers from 1:32 to 1:2. There were no side effects and the procedure was well tolerated with good renal function 500 days post transplantation. Conclusion Ig-TheraSorb®-Immunoadsorption is an alternative method of elimination of harmful antibodies and it enables successful integration of ABO-incompatible transplantation into regular transplantation programs.</description><identifier>ISSN: 1473-0502</identifier><identifier>EISSN: 1878-1683</identifier><identifier>DOI: 10.1016/j.transci.2014.01.006</identifier><identifier>PMID: 24517873</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>ABO Blood-Group System ; ABO incompatible transplantation ; Adult ; Agglutinins ; Antibodies, Monoclonal, Murine-Derived - administration & dosage ; Blood Component Removal - methods ; Health technology assessment ; Hematology, Oncology and Palliative Medicine ; Humans ; Immunoadsorption ; Immunologic Factors - administration & dosage ; Immunosorbent Techniques ; Isoagglutinin-antibody ; Kidney transplantation ; Kidney Transplantation - methods ; Male ; Plasmapheresis ; Rituximab ; Tissue Donors</subject><ispartof>Transfusion and apheresis science, 2014-04, Vol.50 (2), p.263-266</ispartof><rights>Elsevier Ltd</rights><rights>2014 Elsevier Ltd</rights><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c335t-6924db2ccf49d4c5d8141aca35157d716d9d473a997f5b1e166f7d48661324083</citedby><cites>FETCH-LOGICAL-c335t-6924db2ccf49d4c5d8141aca35157d716d9d473a997f5b1e166f7d48661324083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transci.2014.01.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24517873$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hickstein, Heiko</creatorcontrib><creatorcontrib>Koball, Sebastian</creatorcontrib><creatorcontrib>Lehmann, Renate</creatorcontrib><creatorcontrib>Protzel, Chris</creatorcontrib><creatorcontrib>Stein, Kathrin</creatorcontrib><creatorcontrib>Mitzner, Steffen</creatorcontrib><creatorcontrib>Hakenberg, Oliver</creatorcontrib><title>AB0 incompatible kidney transplantation using unspecific immunoadsorption</title><title>Transfusion and apheresis science</title><addtitle>Transfus Apher Sci</addtitle><description>Abstract Background A protocol for ABO-incompatible kidney transplantation with antigen specific immunoadsorption, rituximab and conventional immunosuppression has been successfully implemented in many European centers. We report an alternative method for the elimination of isoagglutinins with a number of advantages – large amount of treatable plasma, parallel removal of other rejection-inducing antibodies, long operating life, favorable cost-benefit ratio. Method We report our first successfully treated case of an ABO-incompatible living donor kidney transplantation using Immunoadsorption with Ig-TheraSorb®. We performed 5 sessions preoperatively and one after transplantation. Per treatment session twice the calculated plasma volume (4400 ml in this patient) was treated. Results Per treatment session the IgM- isoagglutinin-titers were reduced from 1:16 to 1:1 and the IgG- isoagglutinin-titers from 1:32 to 1:2. There were no side effects and the procedure was well tolerated with good renal function 500 days post transplantation. Conclusion Ig-TheraSorb®-Immunoadsorption is an alternative method of elimination of harmful antibodies and it enables successful integration of ABO-incompatible transplantation into regular transplantation programs.</description><subject>ABO Blood-Group System</subject><subject>ABO incompatible transplantation</subject><subject>Adult</subject><subject>Agglutinins</subject><subject>Antibodies, Monoclonal, Murine-Derived - administration & dosage</subject><subject>Blood Component Removal - methods</subject><subject>Health technology assessment</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Immunoadsorption</subject><subject>Immunologic Factors - administration & dosage</subject><subject>Immunosorbent Techniques</subject><subject>Isoagglutinin-antibody</subject><subject>Kidney transplantation</subject><subject>Kidney Transplantation - methods</subject><subject>Male</subject><subject>Plasmapheresis</subject><subject>Rituximab</subject><subject>Tissue Donors</subject><issn>1473-0502</issn><issn>1878-1683</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtv1TAQhS1ERUvhJ4CyZJPgiV_JBtRWPCpV6qJlbfnaE-TbxA52gnT_PQ73woIN3tg6OnNm_A0hb4A2QEG-3zdLMiFb37QUeEOhoVQ-IxfQqa4G2bHn5c0Vq6mg7Tl5mfOeUlDQyxfkvOUCVKfYBbm9uqaVDzZOs1n8bsTqybuAh-p3-jyasBQ9hmrNPnyv1qKh9YO3lZ-mNUTjckzz5nhFzgYzZnx9ui_Jt8-fHm--1nf3X25vru5qy5hYatm33O1aawfeO26F64CDsYYJEMopkK7Iipm-V4PYAYKUg3K8kxJYy2nHLsm7Y-6c4o8V86Inny2OZVSMa9YgWqmYLHHFKo5Wm2LOCQc9Jz-ZdNBA9UZR7_WJot4oagq6UCx1b08t1t2E7m_VH2zF8PFowPLRnx6TLhEYLDqf0C7aRf_fFh_-SbCjD96a8QkPmPdxTaFQ1KBzq6l-2Fa5bRI4LacD9guZ45rv</recordid><startdate>201404</startdate><enddate>201404</enddate><creator>Hickstein, Heiko</creator><creator>Koball, Sebastian</creator><creator>Lehmann, Renate</creator><creator>Protzel, Chris</creator><creator>Stein, Kathrin</creator><creator>Mitzner, Steffen</creator><creator>Hakenberg, Oliver</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201404</creationdate><title>AB0 incompatible kidney transplantation using unspecific immunoadsorption</title><author>Hickstein, Heiko ; Koball, Sebastian ; Lehmann, Renate ; Protzel, Chris ; Stein, Kathrin ; Mitzner, Steffen ; Hakenberg, Oliver</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c335t-6924db2ccf49d4c5d8141aca35157d716d9d473a997f5b1e166f7d48661324083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>ABO Blood-Group System</topic><topic>ABO incompatible transplantation</topic><topic>Adult</topic><topic>Agglutinins</topic><topic>Antibodies, Monoclonal, Murine-Derived - administration & dosage</topic><topic>Blood Component Removal - methods</topic><topic>Health technology assessment</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Immunoadsorption</topic><topic>Immunologic Factors - administration & dosage</topic><topic>Immunosorbent Techniques</topic><topic>Isoagglutinin-antibody</topic><topic>Kidney transplantation</topic><topic>Kidney Transplantation - methods</topic><topic>Male</topic><topic>Plasmapheresis</topic><topic>Rituximab</topic><topic>Tissue Donors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hickstein, Heiko</creatorcontrib><creatorcontrib>Koball, Sebastian</creatorcontrib><creatorcontrib>Lehmann, Renate</creatorcontrib><creatorcontrib>Protzel, Chris</creatorcontrib><creatorcontrib>Stein, Kathrin</creatorcontrib><creatorcontrib>Mitzner, Steffen</creatorcontrib><creatorcontrib>Hakenberg, Oliver</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion and apheresis science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hickstein, Heiko</au><au>Koball, Sebastian</au><au>Lehmann, Renate</au><au>Protzel, Chris</au><au>Stein, Kathrin</au><au>Mitzner, Steffen</au><au>Hakenberg, Oliver</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0 incompatible kidney transplantation using unspecific immunoadsorption</atitle><jtitle>Transfusion and apheresis science</jtitle><addtitle>Transfus Apher Sci</addtitle><date>2014-04</date><risdate>2014</risdate><volume>50</volume><issue>2</issue><spage>263</spage><epage>266</epage><pages>263-266</pages><issn>1473-0502</issn><eissn>1878-1683</eissn><abstract>Abstract Background A protocol for ABO-incompatible kidney transplantation with antigen specific immunoadsorption, rituximab and conventional immunosuppression has been successfully implemented in many European centers. We report an alternative method for the elimination of isoagglutinins with a number of advantages – large amount of treatable plasma, parallel removal of other rejection-inducing antibodies, long operating life, favorable cost-benefit ratio. Method We report our first successfully treated case of an ABO-incompatible living donor kidney transplantation using Immunoadsorption with Ig-TheraSorb®. We performed 5 sessions preoperatively and one after transplantation. Per treatment session twice the calculated plasma volume (4400 ml in this patient) was treated. Results Per treatment session the IgM- isoagglutinin-titers were reduced from 1:16 to 1:1 and the IgG- isoagglutinin-titers from 1:32 to 1:2. There were no side effects and the procedure was well tolerated with good renal function 500 days post transplantation. Conclusion Ig-TheraSorb®-Immunoadsorption is an alternative method of elimination of harmful antibodies and it enables successful integration of ABO-incompatible transplantation into regular transplantation programs.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>24517873</pmid><doi>10.1016/j.transci.2014.01.006</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-0502 |
| ispartof | Transfusion and apheresis science, 2014-04, Vol.50 (2), p.263-266 |
| issn | 1473-0502 1878-1683 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1526736515 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | ABO Blood-Group System ABO incompatible transplantation Adult Agglutinins Antibodies, Monoclonal, Murine-Derived - administration & dosage Blood Component Removal - methods Health technology assessment Hematology, Oncology and Palliative Medicine Humans Immunoadsorption Immunologic Factors - administration & dosage Immunosorbent Techniques Isoagglutinin-antibody Kidney transplantation Kidney Transplantation - methods Male Plasmapheresis Rituximab Tissue Donors |
| title | AB0 incompatible kidney transplantation using unspecific immunoadsorption |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T14%3A36%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0%20incompatible%20kidney%20transplantation%20using%20unspecific%20immunoadsorption&rft.jtitle=Transfusion%20and%20apheresis%20science&rft.au=Hickstein,%20Heiko&rft.date=2014-04&rft.volume=50&rft.issue=2&rft.spage=263&rft.epage=266&rft.pages=263-266&rft.issn=1473-0502&rft.eissn=1878-1683&rft_id=info:doi/10.1016/j.transci.2014.01.006&rft_dat=%3Cproquest_cross%3E1526736515%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1526736515&rft_id=info:pmid/24517873&rft_els_id=S1473050214000081&rfr_iscdi=true |